FINWIRES · TerminalLIVE
FINWIRES

NeOnc Technologies Says Abu Dhabi Clears NEO212 for Phase 2 Brain Cancer Trial

By

NeOnc Technologies (NTHI) said Tuesday it has received investigational new drug clearance from the Abu Dhabi's Department of Health for its brain tumor treatment NEO212, enabling phase 2 evaluation of the therapy in the UAE.

The authorization marks the first international regulatory clearance for NEO212 following completion of phase 1 clinical evaluation and represents a "significant step" toward expanding the program into multiple global markets, the company said.

The clearance also adds an international clinical pathway for NEO212 while discussions continue with the US Food and Drug Administration on a potential registrational pathway for the therapy, the company said.

Shares of NeOnc Technologies were 6% higher in Tuesday trading.

Price: $4.39, Change: $-0.12, Percent Change: -2.66%

Related Articles

Wire

Adaptive Biotechnologies Weighs Separation of Immune Medicine Unit; Shares Fall After Hours

Adaptive Biotechnologies (ADPT) is evaluating strategic and structural alternatives for its immune medicine segment in a plan to separate the business from its minimal residual disease division.A decision on the separation is expected by year-end, the company said Monday in a statement.Adaptive shares fell 5.6% in after-hours trading.

$ADPT
Wire

High Tide Swings to Fiscal Q2 Profit, Revenue Rises; Shares Gain After Hours

High Tide (HITI) reported fiscal Q2 adjusted earnings late Monday of 0.01 Canadian dollars per diluted share, compared with the loss of C$0.04 a year earlier.Three analysts surveyed by FactSet expected a loss of C$0.02.Revenue in the three months ended April 30 rose to C$179.3 million from C$137.8 million a year ago.Analysts surveyed by FactSet expected C$171.2 million.High Tide shares rose 15% in after-hours trading.

$HITI
Wire

Dave & Buster's Entertainment Fiscal Q1 Adjusted Earnings, Revenue Decline

Dave & Buster's Entertainment (PLAY) reported fiscal Q1 non-GAAP net income late Monday of $0.22 per diluted share, down from $0.76 a year earlier.Analysts polled by FactSet expected $0.56.Revenue for the quarter ended May 5 was $559.2 million, down from $567.7 million a year earlier.Analysts expected $580.6 million.Shares of the company were down about 4% in after-hours trading.

$PLAY